의료 진단용 인공지능(AI) 시장 : 전략적 인사이트와 예측(2026-2035년)

The AI in Diagnostics Market is forecast to grow at a CAGR of 21.5%, reaching USD 17.91 billion in 2035 from USD 3.10 billion in 2026.

The global AI in diagnostics market is undergoing rapid transformation, driven by the convergence of rising diagnostic volumes, workforce shortages, and the increasing complexity of clinical data. Artificial intelligence enhances diagnostic decision-making by identifying clinically meaningful patterns within medical images, pathology slides, laboratory results, genomic datasets, and unstructured clinical documentation. Machine learning, deep learning, computer vision, and natural language processing support clinicians by improving detection accuracy, reducing interpretation variability, and prioritizing high-risk cases. Healthcare systems continue to experience increasing diagnostic volumes because aging populations, chronic disease prevalence, precision medicine initiatives, and expanding imaging utilization generate larger quantities of clinical data than conventional workflows can efficiently process. This imbalance increases dependence on AI-assisted interpretation to improve operational efficiency without compromising diagnostic quality. Regulatory authorities are establishing dedicated guidance for artificial intelligence-enabled medical devices because adaptive algorithms require continuous oversight throughout their lifecycle. Regulatory expectations increasingly emphasize transparency, clinical validation, cybersecurity, post-market surveillance, and risk management, encouraging developers to strengthen evidence generation before large-scale commercialization. The strategic importance of AI in diagnostics extends beyond automation because healthcare organizations are seeking integrated platforms that connect imaging systems, laboratory information systems, pathology workflows, genomics platforms, and electronic health records.

Market Drivers

Increasing Diagnostic Imaging Volumes

• Diagnostic imaging demand continues to expand because aging populations and chronic disease prevalence increase the number of patients requiring radiological assessment. Healthcare providers are implementing AI-assisted image analysis to improve workflow efficiency as reporting backlogs are becoming more common across hospitals. This adoption strengthens diagnostic consistency while enabling clinicians to prioritize critical findings without replacing physician oversight.

Expansion of Regulatory Frameworks for AI-Based Medical Devices

• Healthcare regulators continue developing dedicated frameworks for artificial intelligence because software-based medical devices require lifecycle oversight beyond traditional medical equipment. Developers are increasing investments in prospective validation studies as regulatory expectations continue evolving across major markets. This transition supports greater confidence among healthcare providers while improving commercialization opportunities.

Growing Adoption of Precision Medicine

• Precision medicine depends on accurate interpretation of imaging, pathology, molecular diagnostics, and genomic information. Healthcare organizations are integrating AI platforms because conventional analytical approaches cannot efficiently process increasingly complex multimodal datasets. This shift supports personalized diagnosis while improving biomarker identification and treatment selection across oncology and other specialty areas.

Digital Transformation Across Healthcare Systems

• Hospitals continue modernizing diagnostic infrastructure because interoperable digital platforms improve care coordination and operational efficiency. Artificial intelligence solutions are becoming integrated into enterprise imaging systems, laboratory workflows, and electronic health records as healthcare organizations prioritize automation. This structural transition strengthens long-term demand for enterprise-scale AI deployment rather than isolated point solutions.

Market Restraints

• Clinical validation requirements remain extensive because healthcare providers require robust prospective evidence before integrating AI into routine diagnostic workflows. Regulatory requirements continue evolving across jurisdictions, creating longer commercialization timelines for developers seeking multi-region market access. Data privacy, cybersecurity, and interoperability challenges limit implementation because healthcare organizations must comply with stringent patient data protection requirements.

Technology and Segment Insights

By Technology

• Deep learning represents the largest technology platform because complex neural network architectures improve image recognition, pathology interpretation, and predictive analytics across multiple diagnostic applications. Healthcare providers are expanding investments in deep learning solutions as imaging datasets continue increasing in size and complexity. Machine learning, natural language processing, and computer vision represent additional critical technologies.

By Component

• Software constitutes the primary revenue-generating component because artificial intelligence capabilities are delivered through clinical decision support platforms, workflow management systems, image analysis applications, and cloud-based diagnostic solutions. Healthcare organizations are deploying enterprise software platforms as interoperability with hospital information systems becomes increasingly important. Hardware and services represent additional segments.

By Clinical Application

• Oncology represents the leading clinical application because cancer diagnosis increasingly depends on imaging, pathology, molecular profiling, and genomic interpretation. Healthcare institutions are integrating AI across multidisciplinary oncology workflows as precision medicine continues expanding globally. Cardiology, neurology, pulmonology, gastroenterology, and infectious diseases represent significant and growing application areas.

By End User

• Hospitals represent the largest end-user segment because they manage high-volume diagnostic services across multiple specialties. Diagnostic laboratories are adopting AI for workflow optimization and result interpretation. Pharmaceutical and biotechnology companies utilize AI for biomarker discovery and clinical trials.

Competitive and Strategic Outlook

• The competitive landscape features major medical technology companies and specialized AI diagnostic firms. Siemens Healthineers AG distinguishes itself through one of the broadest AI-enabled diagnostic ecosystems spanning radiology, molecular imaging, laboratory diagnostics, and digital health. GE HealthCare Technologies Inc. differentiates itself by combining advanced imaging equipment with AI-enabled workflow orchestration through the Edison Digital Health Platform. Koninklijke Philips N.V. maintains a strong competitive position by integrating AI across diagnostic imaging, image-guided therapy, patient monitoring, and healthcare informatics. Tempus AI, Inc. differentiates itself through its focus on precision medicine by combining AI with clinical, molecular, imaging, and genomic data. Aidoc Medical Ltd. specializes in AI solutions for radiology workflow optimization and emergency care triage. PathAI, Inc. has established a strong competitive position through AI applications for digital pathology, biomarker discovery, and pharmaceutical research.
• Strategic developments include increasing integration of multimodal diagnostics, expansion of digital pathology, and growth of AI adoption in emerging healthcare markets. Companies are forming partnerships with healthcare providers, pharmaceutical companies, and technology vendors to strengthen clinical validation and commercialization. Product launches focus on enterprise software platforms, workflow automation, and precision medicine applications. Companies that successfully combine strong clinical evidence, regulatory expertise, interoperable software platforms, and scalable implementation capabilities are expected to lead the market.

Conclusion

• The AI in diagnostics market is poised for exceptional growth, driven by rising diagnostic volumes, regulatory maturation, precision medicine, and healthcare digitalization. The evolution from pilot implementations toward enterprise-wide deployment is reshaping diagnostic practice. Companies that successfully deliver clinically validated, interoperable, and scalable AI solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding digital health infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global AI in Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Diagnostic Workflow Analysis
• 3.8 AI Adoption Across Diagnostic Specialties
• 3.9 Diagnostic Testing Volume Analysis
• 3.10 Clinical Decision Support Integration
• 3.11 Healthcare Provider Adoption Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging AI Technologies in Diagnostics
• 6.2 Product Innovation Analysis
• 6.3 Clinical Validation and Performance Evaluation Analysis
• 6.4 AI Algorithm Development Trends
• 6.5 Pipeline Analysis
• 6.6 Multimodal AI and Foundation Model Integration
• 6.7 Cloud and Edge AI Deployment Trends
• 6.8 Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global AI in Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology
• 8.2 Analysis by Component
• 8.3 Analysis by Clinical Application
• 8.4 Analysis by Deployment Model
• 8.5 Analysis by End User

9. Global AI in Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Machine Learning
  • 9.1.2 Deep Learning
  • 9.1.3 Natural Language Processing
  • 9.1.4 Computer Vision
  • 9.1.5 Others
• 9.2 By Component
  • 9.2.1 Software
  • 9.2.2 Hardware
  • 9.2.3 Services
• 9.3 By Clinical Application
  • 9.3.1 Oncology
  • 9.3.2 Cardiology
  • 9.3.3 Neurology
  • 9.3.4 Pulmonology
  • 9.3.5 Gastroenterology
  • 9.3.6 Infectious Diseases
  • 9.3.7 Other Clinical Applications
• 9.4 By Deployment Model
  • 9.4.1 Cloud-Based
  • 9.4.2 On-Premise
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Pharmaceutical & Biotechnology Companies
  • 9.5.4 Others

10. Global AI in Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global AI in Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 India
• 11.13 Australia
• 11.14 Brazil
• 11.15 Mexico
• 11.16 Saudi Arabia
• 11.17 United Arab Emirates
• 11.18 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Siemens Healthineers AG
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 GE HealthCare Technologies Inc.
• 13.3 Koninklijke Philips N.V.
• 13.4 Johnson & Johnson
• 13.5 Medtronic plc
• 13.6 Boston Scientific Corporation
• 13.7 Tempus AI, Inc.
• 13.8 Aidoc Medical Ltd.
• 13.9 Viz.ai, Inc.
• 13.10 PathAI, Inc.

14. Global AI in Diagnostics Market Commercial Forecast Analysis

• 14.1 AI-Based Medical Imaging Solutions
• 14.2 AI-Based Digital Pathology Solutions
• 14.3 AI-Powered Clinical Decision Support Systems
• 14.4 AI-Based In Vitro Diagnostic Solutions
• 14.5 AI-Enabled Genomic and Molecular Diagnostic Solutions
• 14.6 AI Software as a Medical Device (AI-SaMD) Platforms

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends